ASCO对CAP/IASLC/AMP肺癌分子检测指南的认可更新
美国临床肿瘤学会(ASCO)对CAP/IASLC/AMP更新的肺癌分子检测指南进行方法学审查和内容评估后予以认可,并做小幅修改。该指南明确了样本细胞量要求、反对用免疫组化检测EGFR表达筛选靶向治疗患者,并新增ROS1、BRAF等检测推荐。
要点
- 任何细胞量充足且保存合格的样本均可检测,方法需能检出低至20%癌细胞中的突变。
- 强烈反对用免疫组化检测EGFR表达来筛选EGFR靶向治疗患者。
- 新增晚期肺腺癌ROS1单独检测及RET、ERBB2、KRAS、MET panel检测推荐。
核心结论
- ASCO专家小组认为CAP/IASLC/AMP分子检测指南推荐清晰、全面且基于最相关科学证据,予以认可并做小幅修改。
研究设计与样本
- ASCO方法学家对指南进行方法学严谨性审查,随后ASCO专家小组审查内容和推荐。
主要发现
- 指南澄清任何细胞量充足且保存合格的样本均可检测,分析方法需能检出低至20%癌细胞中的突变。
- 强烈推荐反对用免疫组化检测EGFR表达来筛选EGFR靶向治疗患者。
- 2018年新增推荐:所有晚期肺腺癌患者进行ROS1单独检测并附加确认检测,以及RET、ERBB2(HER2)、KRAS和MET作为更大panel的一部分检测。
- ASCO还推荐晚期肺腺癌患者进行BRAF单独检测。
关键数值与推荐
- 分析方法必须能检测样本中低至20%癌细胞的突变。
- 强烈推荐反对通过免疫组化评估EGFR表达来选择EGFR靶向治疗患者。
- 推荐所有晚期肺腺癌患者进行ROS1单独检测并附加确认检测。
- 推荐RET、ERBB2(HER2)、KRAS和MET检测作为更大panel的一部分。
- 推荐晚期肺腺癌患者进行BRAF单独检测。
临床怎么用
- 临床可依据指南对肺癌患者样本进行分子检测以筛选靶向酪氨酸激酶抑制剂治疗。
- 避免使用免疫组化检测EGFR表达来筛选EGFR靶向治疗患者。
- 对晚期肺腺癌患者应进行ROS1和BRAF单独检测,并将RET、ERBB2、KRAS、MET纳入panel检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose In response to advances in the field, the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) recently updated their recommendations for molecular testing for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. Methods The molecular testing guideline was reviewed for developmental rigor by methodologists. Then an ASCO Expert Panel reviewed the content and the recommendations. Results The ASCO Expert Panel determined that the recommendations from the CAP/IASLC/AMP molecular testing guideline are clear, thorough, and based upon the most relevant scientific evidence. ASCO endorsed the guideline with minor modifications. Recommendations This update clarifies that any sample with adequate cellularity and preservation may be tested and that analytical methods must be able to detect mutation in a sample with as little as 20% cancer cells. It strongly recommends against evaluating epidermal growth factor receptor (EGFR) expression by immunohistochemistry for selection of patients for EGFR-targeted therapy. New for 2018 are recommendations for stand-alone ROS1 testing with additional confirmation testing in all patients with advanced lung adenocarcinoma, and RET, ERBB2 (HER2), KRAS, and MET testing as part of larger panels. ASCO also recommends stand-alone BRAF testing in patients with advanced lung adenocarcinoma. Recommendations are also provided for testing methods for lung cancers that have a nonadenocarcinoma non-small-cell component, for patients with targetable mutations who have relapsed on targeted therapy, and for testing the presence of circulating cell-free DNA. Additional information is available at www.asco.org/thoracic-cancer-guidelines and www.asco.org/guidelineswiki .
引用
- Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol. 2018. PMID: 29401004. doi:10.1200/JCO.2017.76.7293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。